Stifel Nicolaus Issues Pessimistic Forecast for MaxCyte (NASDAQ:MXCT) Stock Price

MaxCyte (NASDAQ:MXCT) had its price target dropped by research analysts at Stifel Nicolaus from $11.00 to $9.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 194.12% from the company’s current price.

MaxCyte Stock Down 3.8 %

MXCT opened at $3.06 on Wednesday. The stock’s 50 day moving average price is $4.19 and its two-hundred day moving average price is $3.98. The firm has a market capitalization of $324.23 million, a P/E ratio of -9.00 and a beta of 1.35. MaxCyte has a 12-month low of $2.76 and a 12-month high of $5.26.

Institutional Trading of MaxCyte

Institutional investors have recently modified their holdings of the company. Mirabella Financial Services LLP acquired a new position in shares of MaxCyte in the 4th quarter worth approximately $15,392,000. River Global Investors LLP increased its holdings in shares of MaxCyte by 57.7% in the fourth quarter. River Global Investors LLP now owns 3,253,192 shares of the company’s stock valued at $13,494,000 after purchasing an additional 1,190,630 shares in the last quarter. Cadian Capital Management LP lifted its holdings in MaxCyte by 14.1% during the 4th quarter. Cadian Capital Management LP now owns 9,344,424 shares of the company’s stock worth $38,873,000 after buying an additional 1,155,476 shares in the last quarter. AXA S.A. acquired a new stake in shares of MaxCyte in the 4th quarter valued at $4,105,000. Finally, Royce & Associates LP raised its position in shares of MaxCyte by 146.9% during the fourth quarter. Royce & Associates LP now owns 799,873 shares of the company’s stock worth $3,327,000 after acquiring an additional 475,949 shares during the last quarter. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.